Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
0.6242
-0.0108 (-1.70%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 09, 2025
Via
Benzinga
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
June 05, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
April 28, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
April 21, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
↗
April 10, 2025
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Via
Benzinga
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
↗
April 10, 2025
CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.
Via
Stocktwits
Topics
World Trade
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
April 09, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Monday's session: gap up and gap down stocks
↗
April 07, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Tempest Reports Year End 2024 Financial Results and Provides Business Update
March 27, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment
From
Tempest Therapeutics
Via
GlobeNewswire
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
March 13, 2025
Second clinical program entering Phase 2 with data expected 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tuesday's after hours session: top gainers and losers
↗
March 04, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 10, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
January 06, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 30, 2024
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
↗
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 10, 2024
Via
Benzinga
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
↗
October 10, 2024
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 10, 2024
Via
Benzinga
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 10, 2024
The company is preparing for the Phase 3 study start in the first quarter of 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Extends Limited Duration Stockholder Rights Plan
October 10, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
September 18, 2024
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study
From
Tempest Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
